Novo Nordisk NVO lost 2.2% on Jun 26 after the company announced the failure of a late-stage study evaluating ocedurenone to treat patients with uncontrolled hypertension and advanced chronic kidney ...
Source LinkNovo Nordisk NVO lost 2.2% on Jun 26 after the company announced the failure of a late-stage study evaluating ocedurenone to treat patients with uncontrolled hypertension and advanced chronic kidney ...
Source Link
Comments